IMBiologics (KRX: 493280)

Suwon-si, South Korea · Founded 2020 · Publicly Held

IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. IMBiologics (KRX: 493280) is based in Suwon-si, South Korea and was founded in 2020. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $262 million (Mar 2026). It has raised $99.1 million.

Last price · $/share
—
Implied valuation
$261.7M
Total raised
$99.1M
Last round
—

Who backs IMBiologics (KRX: 493280)?

22 investors
InvestorType
KB InvestmentVenture capital
Korea Development BankOther
IMM InvestmentAsset manager
Shinhan Venture InvestmentVenture capital
Partners InvestmentVenture capital
CJ InvestmentVenture capital
Korea Investment & SecuritiesOther
K2 Investment PartnersVenture capital
Shinhan SecuritiesOther
Woori BankOther
+ 12 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

IMBiologics (KRX: 493280) investors

22 investors are on record for IMBiologics (KRX: 493280), including KB Investment, Korea Development Bank, IMM Investment and Shinhan Venture Investment. By type, the record holds 5 venture capital firms and 1 asset manager.

Free account
More of IMBiologics (KRX: 493280) with a free account
  • ·The complete investor list: 22 names
  • ·Watch IMBiologics (KRX: 493280): the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 22 firms already write checks for companies like IMBiologics (KRX: 493280). Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View